Previous 10 | Next 10 |
home / stock / otlkw / otlkw news
MONMOUTH JUNCTION, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...
Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases Terry Dagnon, COO, and Jeff Evanson, CCO, of Outlook Therapeutics share the clinical rationale and regulatory framework for de...
MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinalȂ...
All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in secon...
Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J., Nov. 19, 2020 (GLOBE NEWSW...
Dr. Rahhal , a leading retinal clinician, offer ed insight on wet AMD treatment and the p otential of ONS-5010/ LYTENA VA ™ (bevacizumab-vikg) , if approved, to improve available treatment options ...
MONMOUTH JUNCTION, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinalȂ...
Full enrollment of 195 subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or comple...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Series A Warrant Company Name:
OTLKW Stock Symbol:
NASDAQ Market:
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...
Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...